Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
200 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Gapped Up | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | -3.88% | |
Upper Bollinger Band Touch | Strength | -3.88% | |
Upper Bollinger Band Walk | Strength | -3.88% | |
Gapped Up | Strength | -3.88% | |
Upper Bollinger Band Touch | Strength | -3.88% | |
Upper Bollinger Band Walk | Strength | -6.06% |
Alert | Time |
---|---|
Gap Up Closed | about 16 hours ago |
Gap Up Partially Closed | about 16 hours ago |
20 DMA Support | about 16 hours ago |
200 DMA Support | about 16 hours ago |
60 Minute Opening Range Breakdown | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
SELLAS Life Sciences Group, Inc. Description
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Solid Tumors Cancer Treatment Oncology Breast Cancer Acute Myeloid Leukemia Immunotherapies Antineoplastic Drugs Ovarian Cancer Treatment Of Breast Cancer Hematologic Malignancies Oncolytics Biotech Treatment Of Acute Myeloid Leukemia Novel Cancer Endometrial Cancer Pembrolizumab Gynaecological Cancer Gynaecology Ovarian And Endometrial Cancers
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.72 |
52 Week Low | 0.4986 |
Average Volume | 640,301 |
200-Day Moving Average | 1.23 |
50-Day Moving Average | 1.23 |
20-Day Moving Average | 1.23 |
10-Day Moving Average | 1.27 |
Average True Range | 0.09 |
RSI (14) | 50.25 |
ADX | 20.36 |
+DI | 16.87 |
-DI | 14.71 |
Chandelier Exit (Long, 3 ATRs) | 1.13 |
Chandelier Exit (Short, 3 ATRs) | 1.33 |
Upper Bollinger Bands | 1.35 |
Lower Bollinger Band | 1.11 |
Percent B (%b) | 0.56 |
BandWidth | 19.53 |
MACD Line | 0.02 |
MACD Signal Line | 0.01 |
MACD Histogram | 0.0074 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.41 | ||||
Resistance 3 (R3) | 1.43 | 1.38 | 1.38 | ||
Resistance 2 (R2) | 1.38 | 1.34 | 1.37 | 1.37 | |
Resistance 1 (R1) | 1.31 | 1.31 | 1.29 | 1.30 | 1.36 |
Pivot Point | 1.27 | 1.27 | 1.25 | 1.26 | 1.27 |
Support 1 (S1) | 1.19 | 1.22 | 1.17 | 1.18 | 1.12 |
Support 2 (S2) | 1.15 | 1.19 | 1.14 | 1.11 | |
Support 3 (S3) | 1.08 | 1.15 | 1.10 | ||
Support 4 (S4) | 1.07 |